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Background: Major depressive disorder (MDD) imposes a considerable disease burden on individuals and societies.
Web-based interventions have shown to be effective in reducing depressive symptom severity. However, it is not
known whether web-based interventions may also be effective in preventing the onset of MDD. The aim of this
study is to evaluate the (cost-) effectiveness of an indicated web-based guided self-help intervention (GET.ON Mood
Enhancer Prevention) on the onset of MDD.
Methods/Design: A randomised controlled trial (RCT) will be conducted to compare the (cost-) effectiveness of the
GET.ON Mood Enhancer Prevention training with a control condition exclusively receiving online-based psychoeducation
on depression. Adults with subthreshold depression (N = 406) will be recruited from the general population and
randomised to one of the two conditions. The primary outcome is time to onset of MDD within a 12-months
follow-up period. MDD will be assessed according to DSM-IV criteria as assessed by the telephone-administered
Structured Clinical Interview for DSM-IV (SCID). Time to onset of MDD will be assessed using life charts. Secondary
outcomes include changes on various indicators of depressive symptom severity, anxiety and quality of life from
baseline to post-treatment, to a 6-month and a 12-month follow up. Additionally, an economic evaluation using a
societal perspective will be conducted to examine the intervention’s cost-effectiveness.
Discussion: This is one of the first randomised controlled trials that examines the effect of an indicated guided
self-help web-based intervention on the incidence of major depression. If shown to be effective, the intervention will
contribute to reducing the disease burden due to MDD in the general population.
Trial registration: German Clinical Trial Registration DRKS00004709.
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Cost-effectivenessBackground
Major depressive disorder (MDD) is highly prevalent
[1,2] and has an incidence rate that is high relative to
the number of prevalent cases [3]. The global point
prevalence is estimated at 4.7% with an annual incidence
rate of 3% [4]. Moreover, MDD is related to poorer quality* Correspondence: buntrock@inkubator.leuphana.de
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reproduction in any medium, provided the orof life [5,6], increased mortality [7], and substantial eco-
nomic costs [8-10]. Currently, MDD ranks as the fourth
disorder with the highest disease burden and is projected
to be the leading cause of premature mortality and disabil-
ity in high-income countries by 2030 [11].
The disease burden attributable to MDD might be re-
duced in two ways. The first approach is to treat existing
cases. But despite the availability of effective MDD treat-
ments, such as face-to-face cognitive-behaviour therapy,
behavioural activation therapy or problem-solving ther-
apy [12-14] less than half of depressed patients are
recognised and treated [15]. Furthermore, it is estimatedal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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caused by MDD could be averted assuming the hypo-
thetical scenario of 100% coverage and full compliance
to evidence-based treatments [16,17].
The second approach is reducing the development of
new cases, which requires prevention. Preventive inter-
ventions might be capable of contributing to a further
reduction in disease burden. A recent meta-analysis of
19 randomised controlled trials demonstrated that pre-
ventive interventions based on cognitive behaviour or
interpersonal therapy were able to reduce the incidence
of MDD by 22% [18]. One of these studies also showed
the effectiveness of minimal contact cognitive-behavioural
therapy for depression, based on the ‘Coping with Depres-
sion’ course [19].
Selective prevention aimed at high-risk groups and in-
dicated preventive efforts that target individuals who
show already detectable signs of MDD but who do not
yet meet the diagnostic criteria for the disorder were
particularly effective. Universal prevention aimed at the
general population regardless of any risk profile showed
only small effects.
Indicated prevention has been suggested to be more
“efficient” than selective prevention [20]. “Efficiency” is
here defined in terms of “impact”, that is the number of
cases that would be prevented if the targeted risk indica-
tor were fully blocked in the population and “effort”
reflecting the number needed to be treated to prevent
one new case of MDD. From a clinical point of view, in-
dicated prevention is worthwhile for two reasons. First,
subthreshold depression is a highly prevalent condition
[21] and the burden posed on people affected and the
community is considerable [22,23]. Second, subthreshold
depression is a risk indicator for MDD, as the incidence
rate of MDD is significantly increased in subjects with
subthreshold depression compared to those without ran-
ging from .15 in a general population up to .58 in gen-
eral medical populations and high risk groups [24].
Despite their effectiveness, currently available indi-
cated preventive face-to-face interventions face some
serious limitations. These include (a) difficulties deliver-
ing interventions to the community en masse due to
constraints in the workforce and health care resources
[25,26], (b) limited availability of evidence-based inter-
ventions and clinicians in routine practice, especially in
rural areas, and (c) low participation rates even if access
to those interventions is at little or no costs [27]. There-
fore, new approaches are needed to enhance the impact
of indicated preventive interventions.
Using the Internet to provide (guided) self-help inter-
ventions may help to overcome some of the limitations
of traditional preventive services. Web-based guided
self-help strategies have several advantages over face-to-
face approaches. These include: (a) interventions are moreeasily accessible at any time and place, (b) anonymity is
assured when patients want to avoid stigmatisation, (c) a
greater potential for the integration of acquired skills in
daily life due to an emphasis on the participants’ active
role in (guided) self-help interventions [28] (d) partici-
pants can work at their own pace and go through mate-
rials as often as they want, and (e) elimination of travel
time and costs for both participants and clinicians. Finally
(f), web-based interventions are easily scalable implying
that only a small increase in therapeutic resources is re-
quired for reaching a greater proportion of the eligible
population using these interventions. Thus, marginal costs
per additional user are low due to an economies of scale
effect.
Web-based interventions have shown to be well ac-
cepted by participants [29,30] and to be effective in the
acute treatment of MDD [12] as well as in reducing de-
pressive symptoms both in adults and adolescents
[31,32]. However, although several web-based interven-
tions are labelled as preventive interventions, i.e. ‘Colour
your life’ [33,34], to the best of our knowledge, no study
has yet investigated the (cost-) effectiveness of an indi-
cated guided self-help web-based preventive intervention
on the onset of diagnosed major depressive disorders.Objective and research questions
The aim of this study is to evaluate whether a newly de-
veloped indicated guided self-help web-based interven-
tion (GET.ON Mood Enhancer Prevention) is effective
in preventing the onset of major depressive disorder
when compared to an online psychoeducation-only con-
trol over a 12-months follow-up period. It is expected
that depressive symptomatology will be reduced to a
greater extend in the intervention group than in the
control condition. It is hypothesised that GET.ON Mood
Enhancer Prevention is superior in terms of cost-
effectiveness, and QALY health gains compared to the
psychoeducation-only control.Methods/Design
Design
A two-armed randomised controlled trial (RCT) will be
conducted to compare GET.ON Mood Enhancer Pre-
vention with a psychoeducation-only control condition.
Measurements will be taken at baseline, post-treatment
(6 weeks), 6, and 12 months follow-up (after randomisa-
tion). Telephone-administered Semi-Structured Diagnos-
tic Interviews (SCID) will be conducted at baseline, 6- and
12-months follow-up with the SCID/DSM-IV section for
mood disorders (see Figure 1 for a detailed overview of
the study design). The study is approved by the Medical
Ethics Committee of the Philipps University Marburg
(No. 2012-35 K).
Figure 1 Overview of study procedure.
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We will include adults (a) age 18 and above who (b) suf-
fer from subthreshold depression (Centre for Epidemio-
logical Studies Depression Scale (CES-D) ≥ 16) but do
not meet DSM-IV criteria for a major depressive epi-
sode, (c) have Internet access, and (d) are willing to give
informed consent. We will exclude subjects who (a)
meet DSM-IV criteria for (a) current major depressive
episode, (b) a bipolar disorder, or (c) a psychotic dis-
order. Additional exclusion criteria are: (d) a history of a
major depressive disorder in the past six months (based
on Kupfer [35]), (e) currently receiving psychotherapy
for any kind of mental health problems, (f ) being on a
waiting list for psychotherapy, (g) receiving psychother-
apy in the past six months, and (h) showing a notable
suicidal risk, as indicated through a score greater 1 in
the Beck Depression Inventory (BDI) Item 9 (“I feel I
would be better off dead”).
Recruitment
Participants will be recruited from March 2013 to
February 2014 via the GET.ON research website [36] that
is announced in newspapers, on-air media and related
websites. The research website provides information about
the GET.ON Mood Enhancer Prevention training and
details about the study. Additionally, a major healthinsurance company will support the recruitment by pla-
cing the information leaflet on its website. Individuals in-
terested in participating in the study can apply online on
the GET.ON research website by providing the research
team with their e-mail address or by sending directly an e-
mail to the research team. They do not need to be referred
by their GP or other mental health care specialist.
Assessment of eligibility and randomisation
People who apply online for study participation receive
an information letter via e-mail with detailed informa-
tion about the study procedures. They will be informed
that they can withdraw from the intervention and/or
study at any time without any negative consequences.
Applicants who still want to participate in the study are
asked to complete online screening questionnaires in-
cluding information about the severity of their depres-
sive symptoms (CES-D ≥ 16), whether they are currently
receiving any kind of treatment for any mental health
disease, whether they are on a waiting list for such a
treatment, whether they received such a treatment in
the past six months, and whether they have a high sui-
cidal risk (BDI Item 9 > 1). Subjects screened positive
and who are willing to give informed consent are sched-
uled for a semi-structured clinical interview (SCID) con-
ducted by telephone [37,38]. Participants meeting all of
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have completed the baseline assessment and returned
the informed consent form via post or e-mail will enter
the study and will be randomly allocated to study condi-
tions. Randomisation will take place at an individual
level. Block randomisation will be used to ensure equity
of ample sizes across study conditions. Random blocks
will consist of two allocations each. The allocation will
be done by an independent researcher not otherwise in-
volved in the study using an automated computer-
generated random numbers table.
Blinding
The research staff conducting the semi-structured clin-
ical interviews at 6- and 12-months follow-up will be
blinded to the condition the participants are assigned to.
These include: (a) an explanation to the participants why
it is important not to inform the interviewer about the
condition they were assigned to; (b) a written reminder
for the interviewer in the interview manual to ask the
participant not to inform him/her about the randomisa-
tion status; (c) written and verbal reminders to the pa-
tient before each interview; and (d) a documentation
after each assessment of whether or not the interviewer
is still blind to treatment condition. With regard to the
latter, the interviewer will be asked to guess each partici-
pant’s randomisation status and these guesses will be
compared with the actual status. Cohen’s kappa will be
computed to clarify whether hit rates differ from what
can be expected from chance. In case of evidence for
blinding break down, the interviewer will be changed to
the second outcome interview.
Intervention
Get.ON mood enhancer prevention
The GET.ON Mood Enhancer Prevention training con-
sists of six lessons. Participants are advised to do two
lessons a week but at least one. Consequently, the train-
ing lasts 3 to 6 weeks. However, participants are not ex-
cluded from the intervention if they do not manage to
complete one lesson a week. Lessons consist of text, ex-
ercises, and testimonials. Each lesson includes interactive
elements such as audio and video clips. Audio sequences
introduce relaxation exercises, whereas video clips are
used to explain theoretical frameworks, such as the con-
cept of behavioural activation, in a user-friendly way. A
strong focus lies on transfer tasks (homework assign-
ments) to integrate newly acquired strategies and
techniques into daily life. As an optional component,
participants can choose to receive a set of about 42 stan-
dardised text-messages supporting them to integrate the
learned techniques into their everyday life. An example
of such a text-message would be “Everyone has his own
strategies to vanquish the inner temptation. What helpsyou?” In the beginning of each subsequent lesson, partic-
ipants are invited to reflect on their experiences with the
newly acquired skills. The contents are adaptively tai-
lored to the specific needs of the individual participant
by continuously asking participants to respond by
choosing among various response options. Subsequent
content is then tailored to the participant’s response. For
example, participants are asked whether to work on an
elective module or not and if so they can choose which
module they want to work on.
GET.ON Mood Enhancer Prevention is based on ele-
ments from behaviour therapy (BT) [39] and problem-
solving therapy (PST) [40]. These therapeutic elements
are often found in psychological treatments for sub-
threshold depression [41]. Interventions using BT and
the combination of BT and PST have been shown to ef-
fectively prevent the onset of major depressive disorder
(i.e. [42,43]). In BT, a strong focus rests on daily pleasur-
able activity scheduling that is integrated in each lesson
(Additional file 1: Screenshots of the GET.ON Mood
Enhancer Prevention intervention page 3). The PST ele-
ments implemented in GET.ON Mood Enhancer Preven-
tion have been used in various web-based interventions,
such as the Dutch web-based “Alles onder Controle”
course, which has been shown to be effective in reducing
depressive symptomatology across several randomised
controlled trials [44,45]. In the current study, PST consists
of three steps. First, participants make a list of things that
matter most to them in their lives. Second, participants list
all their problems and worries and divide them into ‘man-
ageable’ and ‘unmanageable’. Finally, they are invited to
think about activities on how to solve the manageable
problems. The main focus in problem-solving therapy is
to tackle those problems that are manageable by means of
a six-step procedure: (1) defining the problem, (2) defining
the target state, (3) brainstorming about possible solutions
and choosing the best one, (4) making a plan how to im-
plement this solution, (5) actually putting the solution into
practice, and (6) evaluating the outcome. Finally, partici-
pants make a plan for the future on how they are going to
accomplish their goals and those things that are most im-
portant to them in their lives (Additional file 1 page 2). In
addition to the BT and PST elements, in the last three les-
sons participants are offered three elective modules target-
ing sleep hygiene, relaxation techniques, and dealing with
worrying thoughts, respectively.
During the training, participants are supported by an
online-trainer. The total time a trainer spends on a par-
ticipant is approximately two hours. Trained and super-
vised graduate students and health care professionals
will provide guidance. Participants will communicate
with their trainer trough the internal messaging function
of the system on which GET.ON Mood Enhancer Pre-
vention is implemented. The guidance provided by the
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the exercises.
Psychoeducational-only condition
The psychoeducational intervention is also web-based
and it is implemented on the same platform as GET.ON
Mood Enhancer Prevention. Psychoeducational inter-
ventions have been shown to be effective in reducing
depressive symptoms [46]. In the current study, the
psychoeducational intervention is based on the German
S3-Guideline/National Disease Management Guideline
Unipolar Depression [47]. It informs participants about
the nature and evidence-based treatments of depression
including information about symptoms and sources of
help. They can go through the material as often as they
want to. In this study, the psychoeducational intervention
does neither require participants to do explicit homework
assignments nor is any support by a trainer or other men-
tal health care specialist offered to participants.
Sample size calculation
We assume an absolute risk reduction of at least 10% for
the incidence of major depressive disorder (MDD) be-
tween intervention and control group as clinically rele-
vant. Based on previous studies evaluating interventions
directed at the prevention of MDD, we expect a mean
incidence of MDD in the control group of 25% within






CES-D Depressive symptom severity
EuroQol Quality of life
SF-12 Subjective functioning/Quality of life




Pearlin Mastery Scale Internal locus of control
PSWQ (Ultra-brief) Worrying thoughts
ISI Insomnia Severity
CEQ Patient expectancy/treatment credibility
ATSPPH-SF Attitudes toward seeking professional psychologica
Course evaluation Participants’ satisfaction with the GET.ON Mood
Enhancer Prevention training
INEP Side-effects of psychotherapypower of 80%, an alpha of 0.05, a relative risk reduction
of 40%, and an attrition rate of 20%, we will need 406
participants to demonstrate an absolute risk reduction of
10% between the groups using log rank survival analyses
(calculated using PASS 12).
Outcome measurements
For an overview of assessment at baseline, post-treatment,
6-and 12-month follow-up see Table 1.
Primary outcome
The primary outcome is time to onset of MDD within a
12-months follow-up period. Major depressive disorder
will be assessed according to DSM-IV criteria as assessed
by the telephone-administered Structured Clinical Inter-
view for DSM-IV (SCID) at 6 and 12 months [37,38].
The inter-rater agreement of the Axis I disorders is
moderate to excellent [51]. The agreement between
face-to-face and telephone SCID interviews as indicated
by the kappa coefficient is considered to be excellent
[52]. Time to onset of MDD will be assessed using life
charts. Life events are recalled by using a calendar method
after which the presence of depressive symptoms at each
month during the follow-up period is determined. SCIDs
will be conducted by trained psychologists who are blind
to treatment condition. The interviews will be recorded to
examine inter-rater reliability. Disagreement shall be
solved by discussion and the agreed rating will be used forTime of measurement
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by an experienced psychotherapist (gold standard) and
this rating will be used for analysis.
Secondary outcomes
Self-report data will be collected using a secured online-
based assessment system (AES, 256-bit encrypted).
Depressive symptomatology
The depressive symptom level will be assessed with the
German version of the Center for Epidemiological Stud-
ies Depression Scale (CES-D) [53]. The CES-D is a self-
report scale and consists of 20 items, each scored 0–3,
covering four domains: depressive affect, somatic com-
plaints/activity inhibition, positive affect, and interper-
sonal difficulties. The total score ranges from 0–60, with
a higher score indicating more severe depressive symp-
toms. A cut-off of 16 is usually regarded as indicating
clinically relevant depressive symptom severity. The reli-
ability of the CES-D has been shown to be excellent (in-
ternal consistency of Cronbach’s α = .89) [53].
Quality of life
Health-related quality of life will be assessed with two
multidimensional generic measures, i.e., the EuroQol
[54] and the SF-12v1 Health Survey [55]. The EuroQol
entails the EQ-5D and a visual analogue scale. The EQ-
5D consists of five items covering five dimensions (mo-
bility, self-care, usual activities, pain/discomfort, and
anxiety/depression), each of which is rated as causing
‘no problems’, ‘some problems’, or ‘extreme problems’.
The SF-12v1 has 12 items covering eight health domains
(physical functioning, role functioning (physical and
emotional), bodily pain, general health, vitality, social
functioning, and mental health). The SF-12 generates
two summary scores, the physical and mental health
summary scores, respectively.
Anxiety
Anxiety will be measured with the German version of
the anxiety subscale of the Hospital Anxiety and Depres-
sion Scale (HADS-A) [56,57]. The anxiety subscale con-
sists of seven questions and each is scored from 0-3
meaning that the total scores ranges from 0-21 where a
score between 0-7 indicates no anxiety, between 8 and
10 possible anxiety, and above 11 or 12 a clinical anxiety
disorder. Psychometric properties are well established
(Cronbach’s α ranging from .63-.93) [58].
Problem-solving skills
Problem-solving ability (i.e., generalised appraisal, be-
liefs, expectancies, and emotional responses) will be
measured with two subscales of the Social Problem-
Solving Inventory-Revised (SPSI-R). The positive problemorientation (PPO) subscale will represent a constructive
dimension whereas the negative problem orientation
(NPO) subscale is viewed as a dysfunctional dimension.
Both subscales have displayed strong psychometric prop-
erties in former studies (Cronbach’s α = .76; .83) [59].
Behavioural activation
Participants’ activation towards goals/values and pleasant
activities and avoidance behaviours will be measured
with the BADS-Short Form (BADS-SF) [60]. The BADS-
SF entails 9 items comprising two subscales (activation
and avoidance). The items are rated on a 7-point Likert-
type scale. Higher scores indicate that the individual
scores high on the area of interest. The BADS-SF shows
good psychometric properties (Cronbach’s α = .82) [60].
Mastery (internal locus of control)
Internal locus of control will be measured with the Pearlin
Mastery Scale [61]. The Pearlin Mastery Scale consists of
7 items and each is rated on a 4-point Likert scale. The
higher the score, the more the individual perceives having
control over situations (internal mastery). A lower score
points to external mastery meaning that the individual
generally has the feeling that things are out of his or her
control. The psychometric properties of this scale are well
established [61].
Worrying
Worrying will be assessed with the ultra-brief version of
the Penn State Worry Questionnaire (PSWQ) [62]. The
ultra-brief version consists of 3 items stemming from
the standard version, with each item being rated on a 7-
point scale. The total score range from 0-18 with higher
scores indicating more worry. The ultra-brief version
shows similar psychometric properties compared to the
standard version (Cronbach’s α = .85) [62].
Insomnia severity
Insomnia severity will be measured because evidence
shows that treating sleep problems can ease depressive
symptoms. Insomnia severity will be assessed with the
Insomnia Severity Index (ISI) [63]. The ISI measures the
nature, severity, and impact of insomnia. It consists of 7
items; each is rated on a 5-point Likert scale resulting in
a total score ranging from 0 to 28. Higher scores indi-
cate more severe insomnia. The ISI is a valid and reliable
instrument to detect cases of insomnia in a population-
based sample. The internal consistency is excellent
(Cronbach’ α = .90) [64].
Treatment credibility/patient expectancy
Training credibility and participants’ expectancy for im-
provement will be measured with the credibility and ex-
pectation questionnaire (CEQ). The CEQ consists of 6
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Likert scale. The psychometric properties of the instru-
ment are well established (Cronbach’s α = .86) [65].
Attitudes toward seeking professional psychological help
The influence of attitudes on mental health care service
utilisation will be measured with the Attitudes Toward
Seeking Professional Psychological Help Scale-SF (ATSPPH-
SF) [66]. The ATSPPH-SF consists of 10 items that are
rated on a 4-point Likert scale yielding a total score ran-
ging from 0-30. High scores indicate positive treatment at-
titudes. The instrument showed good psychometric
properties in a previous study. The internal consistency
ranges from .82 to .84 [67].
Course evaluation
User satisfaction will be measured with a self-designed
questionnaire that is based on the “Satisfaction with Psy-
chotherapy” Questionnaire (ZUF-8, [68]), the German
version of the Client Satisfaction Questionnaire (CSQ-8,
[69]). This self-report measure consists of 8 items meas-
uring the global client satisfaction with the web-based
training. Previous research indicated a high internal
consistency (Cronbach’s α = .91) [70].
Side-effects of psychotherapy
Side-effects of psychotherapy will be measured with the
side-effects of psychotherapy inventory (INEP) [71]. The
INEP consists of 15 items assessing any changes partici-
pants experienced after the completing of the web-based
training in their social and/or work environment that
they directly relate to their participation in the web-
based training.
Key economic outcomes
Clinical endpoints In the cost-effectiveness analyses,
the main outcome will be depression-free years gained.
Depression-free years will be assessed by calculating the
difference in follow-up lengths and the duration of any
major depressive episode (i.e. period of time in weeks
that a person met DSM-IV criteria). In the cost-utility
analysis, quality-adjusted life years (QALYs) will be the
clinical endpoint. QALYs will be obtained from the EQ-
5D (EuroQol) and SF-6D (SF-12v1). The EuroQol will
be used because it is a widely applied quality of life in-
strument and its reliability and validity is well estab-
lished [54]. Theoretically, the EQ-5D generates 243
different health states. Index scores for each of these
health states are available for various countries with
“perfect health” and “death” being assigned values of 1
and 0, respectively. In this study, the index scores de-
rived from a large general population sample in the UK
will be used [72]. For the sensitivity analysis, the German
index scores [73] will be applied. The EQ-5D, however,might suffer from a ceiling effect meaning that a large
number of respondents suffering from mild manifesta-
tions of depressive symptoms report no problems.
Hence, the SF-6D will also be used because it might be
the more appropriate measure for milder conditions, i.e.,
subthreshold depression [74]. The SF-6D contains 6 di-
mensions (each with between 2 and 5 levels) and includes
7 items of the SF-12. The SF-6D generates 7500 different
health states. Utility values will be derived using Brazier’s
algorithm [75,76].
Costs Direct medical (i.e. health care service utilisation)
and direct non-medical costs (i.e. all costs not directly
related to medical services such as transportation) are
measured with the TiC-P, which is a self-report ques-
tionnaire [77]. Indirect non-medical cost stemming from
production losses due to absenteeism and presenteeism
will be assessed with specific modules of the TiC-P. A
catalogue of unit costs (i.e. inpatient, outpatient and re-
habilitative services) and evaluation standards of the As-
sociation of Statutory Health Insurance Physicians [78]




The study will be conducted in agreement with the
CONSORT statement. Differences in the time to onset
of MDD will be analysed in a proportional log rank sur-
vival analysis over a follow-up period of 12 months after
baseline. Time to onset will be the dependent variable in
the survival analyses. Analyses will be done based on the
intention-to-treat (ITT) principle. In addition, per-
protocol analyses will be performed. For participants
who are lost from the trial, available measurements will
be used and then censored at the time of their last ob-
servation. Participants who miss the assessment at 6-
months follow-up, but are then assessed at 12-months
follow-up, will be asked about their current and past
symptoms according to SCID diagnostic criteria since
the diagnostic interview at baseline. This will enable us
to assess the time to onset of a depressive episode and
thus to censoring. One-sided tests will be used for test-
ing unidirectional and two-sided tests for testing bidirec-
tional hypotheses. For all analyses statistical significance
will be set at p < .05. We will calculate the number
needed-to-be-treated (NNT) with GET.ON Mood En-
hancer Prevention to prevent one case of MDD as com-
pared to the control group to estimate the clinical effect
size.
In secondary analyses, hierarchical linear modelling
will be used to assess differences in secondary outcomes,
such as depressive symptom severity, anxiety, and qual-
ity of life. We will also explore the proportion of major
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group by follow-up. For all mixed-model analyses,
Cohen’s d will be calculated by standardising the differ-
ences between baseline and follow-up scores by the
pooled standard deviation of baseline scores.
Economic analyses
It will be checked whether baseline differences exist be-
tween the intervention and control group. If necessary,
statistical techniques will be used to correct for baseline
differences [80]. In the cost-effectiveness analyses, the
incremental cost-effectiveness ratio (ICER) will be stated
as costs per depression-free years gained, whereas the
ICER in the cost-utility analyses will represent the costs
per quality-adjusted life year (QALY) gained. Bootstrap-
ping will be used to test the robustness of the ICERs and
quantify the uncertainty around the ratios that will be
graphically represented on a cost-effectiveness plane.
The bootstrapped ICERs will also be shown in a cost-
effective acceptability curve disclosing the probability
that GET.ON Mood Enhancer Prevention is cost-
effective for a wide range of willingness-to-pay ceilings
[81]. To test the robustness of the base-case findings, a
multi-way sensitivity analysis will be done. An incremen-
tal net benefit regression analysis will be performed to
ascertain which sub-groups benefit more from the inter-
vention in terms of superior cost-effectiveness.
Discussion
Major depressive disorder is a highly prevalent disorder
associated with a considerable loss of quality of life, in-
creased mortality rates, and formidable economic costs.
Due to limited accessibility and efficacy, treating existing
cases only contributes to a partial reduction of disease
burden. Thus, interventions preventing the onset of
MDD should be used to complement treatment-focused
interventions and further reduce the burden of this de-
bilitating disorder. Available face-to-face preventive in-
terventions face, however, limitations. Novel approaches
are needed that go beyond the limits of traditional ser-
vices. The Internet may attract people who do not partici-
pate in face-to-face interventions. Moreover, it potentially
provides the opportunity to offer preventive interventions
to the community en masse. To our knowledge, this is
one of the first randomised controlled trials that examines
the (cost-) effectiveness of a web-based intervention on
the onset of major depression in subjects with subthresh-
old depression.
Limitations of this study include the following. Attri-
tion is a common problem in web-based interventions
[82]. However, providing guidance has been shown to re-
duce attrition rates [12] and the intensity of support of-
fered in this study is considered to keep drop-out to a
minimum. In addition, the psychometric properties ofmost of the secondary outcome measures used in this
trial have not yet been tested in an online environment.
There are several strengths to this study. First, by con-
ducting this trial a significant contribution to the litera-
ture is made as to the best of our knowledge no other
study has yet been undertaken that investigates the effect
on an indicated guided self-help web-based intervention
on the incidence of MDD. Second, Semi-Structured
Diagnostic Interviews (SCID) will be conducted two times
within the 12-month follow-up period to assess the time
to onset of depressive episodes. This frequency of assess-
ments allows for a reasonable temporal precision of onset
of depressive episodes according to DSM-IV criteria.
Third, an economic evaluation will be performed along-
side the randomised controlled trial. If shown to be effect-
ive, this web-based preventive intervention could be easily
disseminated. As a low-threshold intervention, it would be
better accepted among the target group. If shown to be
cost-effective, GET.ON Mood Enhancer Prevention will
be a valuable tool to efficiently reduce the disease burden
attributable to MDD at population level.
Additional file
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